Marine derived hamacanthins as lead for the development of novel PDGFRβ protein kinase inhibitors

Article abstract of DOI:10.3390/md11093209

In this study, we report on pyrazin-2(1H)-ones as lead for the development of potent adenosine triphosphate (ATP) competitive protein kinase inhibitors with implications as anti-cancer drugs. Initially, we identified the pyrazin-2(1H)-one scaffold from hamacanthins (deep sea marine sponge alkaloids) by Molecular Modeling studies as core binding motif in the ATP pocket of receptor tyrosine kinases (RTK), which are validated drug targets for the treatment of various neoplastic diseases. Structure-based design studies on a human RTK member PDGFR (platelet-derived growth factor receptor) suggested a straight forward lead optimization strategy. Accordingly, we focused on a Medicinal Chemistry project to develop pyrazin-2(1H)-ones as optimized PDGFR binders. In order to reveal Structure-Activity-Relationships (SAR), we established a flexible synthetic route via microwave mediated ring closure to asymmetric 3,5-substituted pyrazin-2(1H)-ones and produced a set of novel compounds. Herein, we identified highly potent PDGFR binders with IC ₅₀ values in an enzymatic assay below μ M range, and possessing significant activity against PDGFR dependent cancer cells. Thus, marine hamacanthin-derived pyrazin-2(1H)-ones showing interesting properties as lead for their further development towards potent PDGFR-inhibitors.

Full text of DOI:10.3390/md11093209

Mar. Drugs 2013, 11, 3209-3223; doi:10.3390/md11093209
OPEN ACCESS
marine drugs
ISSN 1660-3397
www.mdpi.com/journal/marinedrugs
Article
Marine Derived Hamacanthins as Lead for the Development of
Novel PDGFRβ Protein Kinase Inhibitors
Boris Pinchuk 1,2, Eugen Johannes 1, Sheraz Gul 2, Joachim Schlosser 1, Christoph Schaechtele 3,
Frank Totzke 3 and Christian Peifer 1,*
1
Institute of Pharmacy, University of Kiel, Gutenbergstraße 76, Kiel D-24118, Germany;
E-Mails: bpinchuk@pharmazie.uni-kiel.de (B.P.); ejohannes@pharmazie.uni-kiel.de (E.J.);
jschlosser@pharmazie.uni-kiel.de (J.S.)
2
European ScreeningPort GmbH, Schnackenburgallee 114, Hamburg D-22525, Germany;
E-Mail: sheraz.gul@screeningport.com
3
ProQinase GmbH, Breisacherstraße 117, Freiburg D-79106, Germany;
E-Mails: c.schaechtele@proqinase.com (C.S.); f.totzke@proqinase.com (F.T.)
* Author to whom correspondence should be addressed; E-Mail: cpeifer@pharmazie.uni-kiel.de;
Tel.: +49-431-880-1137; Fax +49-431-880-1352.
Received: 7 June 2013; in revised form: 1 August 2013 / Accepted: 8 August 2013 /
Published: 26 August 2013
Abstract: In this study, we report on pyrazin-2(1H)-ones as lead for the development of
potent adenosine triphosphate (ATP) competitive protein kinase inhibitors with implications
as anti-cancer drugs. Initially, we identified the pyrazin-2(1H)-one scaffold from
hamacanthins (deep sea marine sponge alkaloids) by Molecular Modeling studies as core
binding motif in the ATP pocket of receptor tyrosine kinases (RTK), which are validated
drug targets for the treatment of various neoplastic diseases. Structure-based design studies
on a human RTK member PDGFR (platelet-derived growth factor receptor) suggested a
straight forward lead optimization strategy. Accordingly, we focused on a Medicinal
Chemistry project to develop pyrazin-2(1H)-ones as optimized PDGFR binders. In order to
reveal Structure-Activity-Relationships (SAR), we established a flexible synthetic route via
microwave mediated ring closure to asymmetric 3,5-substituted pyrazin-2(1H)-ones and
produced a set of novel compounds. Herein, we identified highly potent PDGFR binders
with IC50 values in an enzymatic assay below µM range, and possessing significant
activity against PDGFR dependent cancer cells. Thus, marine hamacanthin-derived
pyrazin-2(1H)-ones showing interesting properties as lead for their further development
towards potent PDGFR-inhibitors.

Mar. Drugs 2013, 11
3210
Keywords: marine sponge derived hamacanthins; pyrazin-2(1H)-ones; receptor tyrosine
kinases; PDGFR inhibitors; anti-cancer activity
1. Introduction
Marine-derived bioactive compounds and their novel chemical scaffolds have been shown to be
attractive starting points for drug discovery programs [1–3]. In this regard, we became interested in the
marine alkaloid family of hamacanthins [4–6]. In the course of our work to develop ATP-competitive
receptor tyrosine kinase (RTK) inhibitors with anti-cancer activity [7–10], we focused on the deep-sea
sponge derived bis-indole alkaloids possessing a 3,5-bis-indole-piperazin-2-one and 3,5-bis-indole-3,
4-dihydropyrazin-2(1H)-one scaffold, respectively (Figure 1) [4,5,11,12]. Recently, cis-3,4-dihydro
hamacanthin B was reported to be a potent bacterial methicillin-resistant Staphylococcus protein
kinase (PK) inhibitor (MRSA-PK inhibitor) with an IC50 value of 0.016 µM and significant selectivity
over human protein kinase isoforms [13]. Furthermore, the 2(1H)-pyrazinone scaffold is present as
core moiety in PK inhibitors [14]. Among human PK are validated drug targets in oncology;
over-activated RTK including VEGFR, PDGFR and c-kit are considered to be major targets for the
development of clinically effective inhibitors [15–17]. In line with this notion, many anti-cancer
compounds that are advanced into the clinic show (group-) selectivity towards VEGFR, FGFR, EGFR,
PDGFRα/β, c-kit, and Flt-3 [18]. Since all PKs from the kinome use ATP as a cofactor for the
phosphorylation of proteins in signal transduction pathways, they share a highly conserved ATP
binding pocket that is the molecular binding site of most PK inhibitors [19]. Thus, small molecular
differences in amino acid identities adjacent to the ATP pocket provide selectivity filters for specific
inhibitors [20]. Therefore, we hypothesize that the hamacanthin-core could serve as a suitable scaffold
for the design of specific PK inhibitors.
Figure 1. Chemical 2D-representation and energy minimized (Schrödinger Suite 2011:
MacroModel, version 9.9, Schrödinger, LLC, New York, NY, 2012) 3D-structures of
hamacanthin family members, and 3,5-bis(6-bromo-1H-indol-3-yl)-1H-pyrazin-2-one as
the concept of this study. The compounds formally show different oxidation status of the
piperazine-2-one core with significant impact to 3,5-diaryl-conformational parameters.
cis-3,4-dihydrohamacanthin B
(A)
5(R)-hamacanthin B
(B)
designed 3,5-diaryl-pyrazin-2(1H)-one
core (C)

Mar. Drugs 2013, 11
3211
Our molecular modeling and docking approaches for the ATP binding pocket of the RTK
VEGF-R2 suggests that only the 3,5-diaryl-pyrazin-2(1H)-one core (Figure 1C) is capable of
occupying the narrow ATP active site of this RTK. Furthermore, the pyrazin-2(1H)-one core was
reported to be a key binding motif to PK [14]. In contrast, neither the 3,5-bis-indole-piperazin-2-one
nor the 3,5-bis-indole-3,4-dihydropyrazin-2(1H)-one core of hamacanthins produced plausible docking
poses. The lack of reasonable binding modes in our modeling studies is mainly due to the chiral
center(s) of the core scaffold positioning the 3,5-bis-indole-moieties out of the piperazin-2-one
ring-plane, and the 5-indole moiety out of the 5,6-dihydropyrazin-2(1H)-one ring plane, respectively
(Figure 1A,B). Our observation is in line with the notion that cis-3,4-dihydrohamacanthin B was
reported to be an allosteric MRSA-PK inhibitor that addresses a tetrameric interface region of the
PK-protein, and was not determined by X-ray analysis as ligand binding to the ATP site [4].
In this study, we designed the aryl-substitution pattern of the 6-membered 3,5-diaryl-pyrazin-2
(1H)-one (compound 5) based on the corresponding 5-membered 3,4-diaryl-2H-pyrrole-2-one
(compound 1, Figure 2), a potent inhibitor developed in a former project showing strong activity
against the RTK VEGF-R2/3 (IC50 = 0.03 µM) and with good efficacy in cellular assays [9].
Figure 2. Structures of the reported potent VEGF-R2/3 inhibitor, compound 1 and the
newly designed and synthesized compound 5 of this study showing comparable decoration
patterns of the aryl moieties.
3,4-diaryl-2H-pyrrole-2-one (1)
2. Results and Discussion
2.1. Synthesis of Designed Compound 5
3,5-diaryl-pyrazin-2(1H)-one (5)
In order to confirm the hypothesis that the pyrazin-2(1H)-ones are suitable scaffolds for PK
inhibitor development, we synthesized compound 5 that involved a modified microwave-mediated ring
closure strategy (Figure 3) [12]. In summary, glyoxylic acid 2 was activated by carbonyldiimidazole
(CDI) and coupled with tryptamine to produce compound 3, which upon DDQ-oxidation yielded
compound 4. Ring closure in the final step to produce the targeted pyrazin-2(1H)-one compound 5 was
straightforward and involved an optimized microwave-mediated reaction using ammonium acetate as
the nitrogen source.
2.2. Biological Evaluation: Activity against PKs
Interestingly, in a preliminary screen [21] involving 24 therapeutically relevant PK targets,
compound 5 inhibited VEGF-R2/3 in the low µM range, and most potently inhibited PDGFRβ with an

Mar. Drugs 2013, 11
3212
IC50 of 0.5 μM. Moreover, compound 5 was shown to exhibit promising selectivity over the other PK
enzymes tested as part of the panel (Table 1). Thus, in order to further enhance potency of this lead
compound towards the PDGFRβ drug target [22] we used a structure-based optimization approach. As
no X-ray structure of the PK domain of PDGFR was available in the public domain, we generated a
homology model of PDGFRβ based on the highly related RTK VEGF-R2 as template structure (pdb
code 2p2h [23] using Schrödinger Prime, version 3.1, Schrödinger, LLC, New York, NY, USA, 2012).
Figure 3. Synthesis of designed compound 5 by microwave mediated ring closure strategy.
Reagents and conditions: (a) 1. CDI, dichloromethane 2. tryptamine; (b) DDQ, THF;
(c) NH4Ac, HAc, microwave heating for 5 min.
6"
5"
7"
4"
7a"
3a"
1'''
1"
1
3"
2
2"
a
2'''
1'
4'
3
2'
3'
6'
5'
b
6"
5"
2
7"
7a"
4"
3a"
1'''
1
3"
1"
2
5"
1
2
6
4"
3a"
2'''
2"
6"
6'
5
c
3
1'
4'
1'
2'
3'
4
6'
5'
5'
3"
2"
7"
7a"
1"
2'
4'
5
3'
Table 1. IC50 values (µM) of compounds 1 and 5 in a panel [21] of 24 therapeutically
relevant PK targets (- indicates no significant PK inhibition was observed at a compound
concentration of 100 µM).
Protein kinase
AKT1
IC50 (µM) for Compound 1
IC50 (µM) for Compound 5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
ARK5
16
46
66
-
Aurora-A
Aurora-B
B-RAF-VE
CDK2/CycA
CDK4/CycD1
COT
66
56
32
23
53
51
9
EGFR
EPHB4
ERBB2
FAK
IGF1R
22
14
SRC

Mar. Drugs 2013, 11
3213
Table 1. Cont.
0.031
VEGF-R2
4
5
VEGF-R3
FLT3
0.037
61
43
60
11
-
36
-
INSR
MET
-
PDGFRβ
PLK1
0.5
-
SAK
10
5
-
TIE2
-
CK2a1
-
-
2.3. Molecular Modeling
Docking compound 5 into the ATP binding site of our homology model of PDGFRβ revealed an
interesting and reasonable binding mode (Figure 4, details of the methodology can be found in
Section 3.2). The key features of the interaction of compound 5 include the hydrogen bonds formed
with the backbone carbonyl of Glu101 and to the amine of Cys103 in the hinge region of the PK,
respectively. The indole ring is located in the hydrophobic pocket I whereas the trimethoxyphenyl
moiety is located in the solvent exposed hydrophobic region II (in accord with a type-I PK
inhibitor [24]).
Figure 4. (A) Homology model of PDGFRβ based on template structure of VEGF-R2
(pdb code 2p2h [23]) and modeled binding mode of compound 5 in the ATP pocket.
(B) Ligand-interaction diagram of compound 5 in the ATP binding site of the PDGFRβ
homology model. Key amino acid residues and hydrogen bonds are shown (see legend).
(A)
(B)

Mar. Drugs 2013, 11
3214
Having demonstrated a rational binding mode for compound 5 in the active site of PDGFRβ, we
subsequently aimed to optimize this compound by performing a virtual screen against a focused set of
compounds, with particular focus upon varying the indole at the pyrazin-2(1H)-one 5′ position, as the
pyrazin-2(1H)-one 3′-(3,4,5-trimethoxyphenyl) moiety had already been shown to be required in order
to inhibit PDGFRβ (Figure 5 [9,25]).
Figure 5. Aryl variation of the pyrazin-2(1H)-one 3′-position and PDGFRβ IC50 values
(µM) of compounds 5–7.
PDGFRβ
#cpd
5
R
IC50 (µM)
0.5
1.5
19
6
7
Figure 6. 5′OH-Indole variation and PDGFRβ-IC50 values (µM) of compounds 5 and 8.
PDGFRβ
#cpd
5
R
IC50 (µM )
0.5
0.3
8

Mar. Drugs 2013, 11
3215
Thus, the indole moiety originally present in the pyrazin-2(1H)-one 5′-position was systematically
varied by synthetically feasible decoration patterns yielding a set of virtual compounds. The subsequent
ligand preparation, docking and scoring campaign using Schrödinger Glide SP (Suite 2012 Glide
version 5.8, Schrödinger, LLC, New York, NY, USA) produced a list with compound 8 as the one that
was predicted to inhibit PDGFRβ most potently (Figure 6). The general binding mode of compound 8
is comparable to the binding pose of compound 5 with the pyrazin-2(1H)-one core addressing H-bonds
to Glu101 and Cys103 (Figure 4), but with the indole-5′OH situated in the hydrophobic pocket II
addressing an additional H-bond to the backbone amide-carbonyl oxygen of Val84.
In accordance with our modeling, compound 8 showed slightly enhanced potency against PDGFRβ
in the PDGFRβ assay (IC50 value = 0.3 µM, Figure 6).
2.4. Biological Activity in Cancer Cell Lines of Compounds 5 and 8
In order to determine the cytotoxic profiles of compounds 5 and 8, they were evaluated in cell
viability assays (Figure 7) including HL-60, a human myeloblastic leukemia cell line, as it has been
shown that the proliferation and differentiation of these cells depend upon PDGFR-signalling [26].
Cells were treated with compounds 5 and 8 and after 48 h incubation, their viability was determined.
The compounds exhibited a differentiated cytotoxic profile. Both compounds were shown to be
cytotoxic against HL-60 cells such that compound 5 was associated with an IC50 value of 0.026 µM
and exhibited a significantly stronger anti-proliferative effect than compound 8 that had an IC50 value
of 30 µM. This is in sharp contrast to the data from isolated PDGFRβ assay and may be due to limited
cellular bioavailability of 8. Interestingly, the other cells tested were significantly less affected. This is
in line with the notion that HL-60 cells depend on PDGFR-signaling [26]. However, in our ongoing
studies we are currently investigating further molecular details of the reported selectivity of compound 5
against HL-60 cells.
Figure 7. Determination of cytotoxic profiles of compounds 5 and 8 in cell viability assays
using HL-60, TK 10, 786-0, M 14, and MCF-7 cell lines.

Mar. Drugs 2013, 11
3216
3. Experimental Section
3.1. Chemistry and Synthesis of Test Compounds
13
1H (300 MHz) and C (75 MHz) NMR were recorded on a Bruker Avance III 300 spectrometer
(Rheinstetten, Germany) at 300 K with a multinuclear probe head using the manufacturer’s pulse
programs. The data are reported as follows: chemical shift in ppm from Me4Si (TMS) as external
standard, multiplicity and coupling constant (Hz). NMR spectra were obtained on a 1H (300 MHz) and
13C spectra (75 MHz) were referenced either to TMS or to internal DMSO-d5 (1H NMR δ 2.50) and
internal DMSO-d6 (13C NMR δ 39.5) or internal CHCl3 (1H NMR δ 7.26) and internal CDCl3
(13C NMR δ 77.0). All coupling constants (J values) are quoted in Hz. The following NMR
abbreviations are used: br (broad), s (singlet), d (doublet), t (triplet), m (unresolved multiplet). The
labelling scheme of structures to correlate NMR signals can be found in Supporting Information.
Mass spectra of the compounds were recorded after chromatographic separation. Mixtures were
separated with an Agilent 1100 HPLC system (Waldbronn; Germany) consisting of a thermostated
autosampler, diode array detection and an Agilent Zorbax Eclipse XDB-C8 column (150 × 4.6 mm,
5 µm particle size). Elution was achieved with a solvent gradient system of water and acetonitrile, with
0.1% of acetic acid and a flow rate of 1 mL/min. The eluent flow was splitted to the mass spectrometer.
Mass spectra with nominal resolution were recorded with an Esquire ~LC mass spectrometer
(Bruker Daltonik, Bremen, Germany), with electrospray ionization operating in the positive ion mode,
with the following parameters: drying gas nitrogen 8 L/min, nebulizer 35 psi, dry gas heating 350 °C,
HV capillary 4000 V, HV EndPlate offset −500 V. GC/MS was performed on a HP6890 Series
System. EI-Mass spectra were recorded on a Varian MAT 311A (70 eV). HRMS spectra were
recorded on a MAT-95 (Finnigan).
Melting points/decomposition temperatures were determined on a Büchi apparatus according to Dr.
Tottoli and are uncorrected.
Where appropriate, column chromatography was performed for crude precursors with Merck silica
gel 60 (0.063–0.200 mm) or Acros organics silica gel (0.060–0.200 mm; pore diameter ca. 60 nm).
Column chromatography for test compounds was performed using a La-Flash-System (VWR) with
Merck silica gel 60 (0.015–0.040 mm) or RP8 columns. The progress of the reactions was monitored
by thin-layer chromatography (TLC) performed with Merck silica gel 60 F-245 plates. Where
necessary, reactions were carried out in a nitrogen atmosphere using 4Å molecular sieves. All reagents
and solvents were obtained from commercial sources and used as received (THF was used after
distillation over K/benzophenone). Reagents were purchased from Sigma-Aldrich Chemie, Steinheim,
Germany; Lancaster Synthesis, Mühlheim, Germany or Acros, Nidderau, Germany.
HPLC analysis was performed on a Hewlett-Packard HP 1090 Series II using a Thermo Betasil C8
(150 × 4.6, 5 µM) column (mobile phase flow 1.5 mL/min, gradient KH2PO4 buffer pH 2.3/methanol,
UV-detection 230/254 nm). All key compounds were proven by this method to show ≥98% purity.
3.1.1. Synthesis of Compound 3
CDI (1.1 equivalent) was added to a solution of 1 equivalent 2-oxo-2-(3,4,5-trimethoxyphenyl)acetic
acid (2) in N-methylpyrrolidone and reacted at room temperature for 1 h. Then, tryptamine (1 equiv)

Mar. Drugs 2013, 11
3217
was added and the mixture was stirred overnight. Then, water was added to quench the reaction and
the mixture was extracted three times with EtOAc. The combined organic phase was evaporated
under reduced pressure and the residue purified by flash silica gel chromatography to afford
N-[2-(1H-indol-3-yl)ethyl]-2-oxo-2-(3,4,5-trimethoxyphenyl)acetamide (3). Yield: (2.2 g, 91%); mp
119 °C; 1H NMR (300 MHz, DMSO-d6) δ: 2.98 (t, J = 7.3 Hz, 2H, CH2-2′″), 3.57 (dt, J = 7.1, 6.1 Hz,
2H, CH2-1′″), 3.77 (s, 9H, 3 OMe), 6,98 (t, J = 6.9 Hz, 1H, H-5″), 7.07 (t, J = 7.0 Hz, 1H, H-6″), 7.20 (d,
J = 2.3 Hz, 1H, H-2″), 7.28 (s, 2H, H-2′,6′), 7.34 (d, J = 8.0 Hz, 1H, H-7″), 7.57 (d, J = 7.7 Hz, 1H,
H-4″), 8.99 (t, J = 5.75 Hz, 1H, CONH), 10.82 (s, 1H, NH-1″); 13C NMR (75 MHz, DMSO-d6) δ: 24.8
(CH2-2′″), 39.1 (CH2-1′″), 56.0 (2′,5′-OMe), 60.3 (4′-OMe), 107.3 (CH-2′,6′), 111.3 (CH-7″), 111.4
(Cq-3″), 118.2 (CH-5″,4″), 120.9 (CH-6″), 122.7 (CH-2″), 127.1 (Cq-3a″), 128.0 (Cq-1′), 136.2 (Cq-7a″),
143.1 (Cq-4′), 152.8 (Cq-3′,5′), 164.6 (CO-1), 188.9 (CO-2); LC-MS m/z 383 [M + H]+.
3.1.2. Synthesis of Compound 4
To a solution of 3 in THF/H2O (9:1) at 0 °C, DDQ (1.5 equiv. dissolved in THF) was added
dropwise and stirred for 1 h. Then the solvent was evaporated to dryness. To the residual mixture,
methanol was added. The precipitate was filtered off and washed with H2O and methanol to afford
N-[2-(1H-indol-3-yl)-2-oxo-ethyl]-2-oxo-2-(3,4,5-trimethoxyphenyl)acetamide (4). Yield: (363 mg, 58%);
1
mp 201 °C; H NMR (300 MHz, DMSO-d6) δ: 3.80 (s, 3H, OMe), 3.93 (s, 6H, 2 OMe), 4.69 (d,
J = 6.0 Hz, 2H, CH2-1″), 7.23 (m, 2H, H-5″,6″), 7.51 (m, 1H, H-7″), 7.57 (s, 2H, H-2′,6′), 8.16 (m, 1H,
13
H-4″), 8.51 (d, J = 3.15 Hz, 1H, H-2″), 9.21 (t, J = 5.9 Hz, 1H, CONH), 12.08 (s, 1H, NH-1″); C
NMR (75 MHz, DMSO-d6) δ: 45.4 (CH2-1′″), 56.1 (2′,5′-OMe), 60.3(4′-OMe), 107.5 (CH-2′,6′), 112.2
(CH-7″), 113.8 (Cq-3″), 121.0 (CH-4″), 122.0, 122.9 (CH-5″,6″), 125.4 (Cq-3a″), 128.2 (Cq-1′), 133.9
(CH-2″), 136.4 (Cq-7a″), 143.1 (Cq-4′), 152.9 (Cq-3′,5′), 166.3 (CO-1), 189.1 (CO-2), 189.7 (CO-2′″);
LC-MS m/z 397 [M + H]+.
General procedure for pyrazinone ring closure using microwave synthesis (compounds 5, 6
and 8a) [27].
A microwave vial (5 mL) was equipped with ammonium acetate (10 equiv) and a solution of
diketone 4 [27] (1 equiv) in acetic acid (3 mL). The vial was sealed and stirred at 160 °C for 4 min in a
microwave synthesizer (CEM Discover). The reaction vessel was cooled to rt when H2O was added to
precipitate the pyrazinone, which was filtered off. The pyrazinone was purified by preparative HPLC
(RP-phase) to afford the test compound ≥98% purity.
3.1.3. Synthesis of Compound 5
By using the general procedure for pyrazinone ring closure we obtained 5-(1H-indole-3-yl)-3-(3,
4,5-trimethoxyphenyl)pyrazin-2(1H)-one (5). Yield after final purification: (31 mg, 11%); mp 293 °C;
1H NMR (300 MHz, DMSO-d6) δ: 3.76 (s, 3H, OMe), 3.88 (s, 6H, 2 OMe), 7.12 (m, 2H, H-5″,6″),
7.44 (m, 1H, H-7″), 7.90 (s, 1H, H-6), 7.92 (d, J = 2.6 Hz, 1H, H-2″), 8.01 (s, 2H, H-2′,6′), 8.30 (d,
13
J = 7.4 Hz, 1H, H-4″), 11.34 (s, 1H, NH-1″), 12.53 (s, 1H, NH-1); C NMR (75 MHz, DMSO-d6)
δ: 55.8 (2′,5′-OMe), 60.1 (4′-OMe), 106.0(CH-2′,6′), 111.8 (Cq-7″) 112.1(Cq-3″), 119.4, 120.4, 121.5
(CH-4″,5″,6″), 123.1 (CH-2″,6), 124.8 (Cq-3a″), 131.9 (Cq-1′,7a″), 136.7 (Cq-3,5), 138.9 (Cq-4′), 152.3

Mar. Drugs 2013, 11
3218
(Cq-3′,5′), 154.1 (CO-2); LC-MS m/z 378 [M + H]+. HRMS: m/z calculated for [M]+ C21H19N3O4:
377.1375; found 377.1363.
3.1.4. Synthesis of Compound 6
By using general procedure for pyrazinone ring closure, 3-(3,4-dimethoxyphenyl)-5-(1H-indol-3-
yl)-1H-pyrazin-2-one (6) was synthesized from N-[2-(1H-indole-3-yl)-2-oxoethyl]-2-(3,4-dimethoxy
1
phenyl)-2-oxoacetamide [27]. Yield: (50 mg, 51%); mp 259 °C; H NMR (300 MHz, DMSO-d6)
δ: 3.84 (s, 3H, OMe), 3.87 (s, 3H, OMe), 7.12 (m, 3H, H-3′,5″,6″), 7.44 (d, J = 7.4 Hz, 1H, H-7″), 7.81
(s, 1H, H-6), 7.90 (d, J = 2.6 Hz, 1H, H-2″), 8.18 (d, J = 1.9 Hz, 1H, H-6′), 8.25 (d, J = 7.7 Hz, 1H,
13
H-4″), 8.30 (dd, J = 8.6, 1.9 Hz, 1H, H-2′), 11.34 (s, 1H, NH-1″), 12.40 (s b, 1H, NH-1); C NMR
(75 MHz, DMSO-d6) δ: 55.3, 55.5 (2 OMe), 110.9 (CH-3′), 111.4 (CH-6″), 111.8 (CH-7″), 112.3
(Cq-3″), 119.4 (CH-6′), 120.4 (CH-4″), 121.4 (CH-5″), 122.1 (CH-2′), 123.1 (CH-2″,6), 124.8
(Cq-3a″), 129.3 (Cq-1′), 136.7 (Cq-7a″), 148.1 (Cq-3″,5″,5′), 150.2 (Cq-4′), 154.1 (CO-2); LC-MS m/z
348 [M + H]+. HRMS: m/z calculated for [M]+ C20H17N3O3: 347.1270; found: 347.1254.
3.1.5. Synthesis of Compound 7
By using general procedure for pyrazinone ring closure, 3-(4-methoxyphenyl)-5-(1H-indol-3-yl)-
1H-pyrazin-2-one (7) was synthesized from N-[2-(1H-indole-3-yl)-2-oxoethyl]-2-(4-methoxyphenyl)-2-
1
oxoacetamide [27]. Yield: (200 mg, 58%); mp 232 °C; H NMR (300 MHz, DMSO-d6) δ: 3.84 (s, 3H,
OMe), 7.06 (d, J = 9.1 Hz, 2H, H-3′,5′), 7.10-7.18 (m, 2H, H-5″,6″), 7.43 (d, J = 7.1 Hz, 1H, H-7″), 7.78
(s, 1H, H-6), 7.88 (d, J = 2.6 Hz, 1H, H-2″), 8.15 (d, J = 7.2 Hz, 1H, H-4″), 8.50 (d, J = 9.0 Hz, 2H,
13
H-2′,6′), 11.34 (s, 1H, NH-1″), 12.42 (s, 1H, NH-2); C NMR (75 MHz, DMSO-d6) δ: 55.2 (OMe),
111.7 (CH-7″), 112.3 (Cq-3″), 113.4 (CH-3′,5′), 119.5 (CH-6″), 120.2 (CH-7″), 121.4 (CH-5″), 123.2
(CH-2″,6), 124.7 (Cq-3a″,5), 129.1 (Cq-1′), 130.0 (CH-2′,6′), 136.7 (Cq-3,7a″), 154.2 (CO-2), 160.3
(Cq-4′); LC-MS m/z 318 [M + H]+. HRMS: m/z calculated for [M]+ C19H15N3O2: 317.1164;
found: 317.1175.
3.1.6. Synthesis of Compound 8a
By using general procedure for pyrazinone ring closure 5-(5-benzyloxy-1H-indol-3-yl)-3-(3,4,5-
trimethoxyphenyl)-1H-pyrazin-2-one, compound 8a was synthesized from N-[2-(5-benzoxy-1H-indol-
3-yl)-2-oxo-ethyl]-2-oxo-2-(3,4,5-trimethoxyphenyl)acetamide [27]. Yield: (220 mg, 76%); mp
231 °C; 1H NMR (300 MHz, DMSO-d6) δ: 3.73 (s, 3H, OMe), 3.81 (s, 6H, 2 OMe), 5.09 (s, 2H, CH2),
6.93 (dd, J = 8.8, 2.40 Hz, 1H, H-6″), 7.32–7.46 (m, 6H, H-7″, 5 H-Bn), 7.88 (s, 1H, H-6), 7.90 (d,
J = 2.5 Hz, 2H, H-2″,4″), 7.97 (s, 2H, H-2′,6′), 11.22 (d, J = 2.5 Hz, 1H, NH-1″), 12.36 (s, 1H, NH-1);
13C NMR (75 MHz, DMSO-d6) δ: 55.9 (2 OMe), 60.1 (OMe), 70.3 (CH2), 105.4 (CH-4″), 106.2
(CH-2′,6′), 111.1 (CH-6″), 111.7 (Cq-3″), 112.1 (CH-7″), 124.0 (CH-2″,6), 125.3 (Cq-3a″), 127.7,
127.7, 128.3 (5 CH-Bn), 132.0 (Cq-7a″), 132.2 (Cq-1′,3a″), 137.6 (Cq-3,5), 139.0 (Cq-4′), 152.3
(Cq-3′,5′), 152.8 (Cq-5″), 154.1 (CO-2); LC-MS m/z 484 [M + H]+. HRMS: m/z calculated for [M]+
C28H25N3O5: 483.1794; found: 483.1776.

Mar. Drugs 2013, 11
3219
3.1.7. Synthesis of Compound 8
A microwave vial (5 mL) was equipped with compound 8a (100 mg), cyclohexene (90 mg), Pd/C
10% (20 mg) and methanol (1.5 mL). The vial was sealed and stirred 10 min at 100 °C in a microwave
synthesizer. The solution was filtered and cooled to room temperature to form a precipitate which was
filtered and washed with methanol and Et2O to afford 5-(5-hydroxy-1H-indole-3-yl)-3-(3,4,5-trime
thoxyphenyl)pyrazin-2(1H)-one, compound 8. Yield: (52 mg, 64%); mp 340 °C; 1H NMR (300 MHz,
DMSO-d6) δ: 3.76 (s, 3H, OMe), 3.88 (s, 6H, 2 OMe), 6.68 (dd, J = 8.7, 2.33 Hz, 1H, H-6″), 7.23 (d,
J = 8.6 Hz, 1H, H-7″), 7.64 (d, J = 2.2 Hz, 1H, H-4″), 7.79 (s, 1H, H-6), 7.80 (d, J = 2.7 Hz, 1H, H-2″),
8.00 (s, 2H, H-2′,6′), 8.67 (s, 1H, OH), 11.05 (d, J = 2.4 Hz, 1H, NH-1″), 12.47 (s, 1H, NH-1); 13C NMR
(75 MHz, DMSO-d6) δ: 55.7 (2 OMe), 60.1 (OMe), 104.7 (CH-4″), 106.0 (CH-2′,6′), 111.3 (Cq-3″),
111.8, 111.9 (CH-6″,7″), 123.5 (CH-2″,6), 125.7 (Cq-4′), 131.9 (Cq-1″,7a″), 132.8 (Cq-3a″), 138.8
(Cq-4′), 151.2 (COH-5″), 152.3 (Cq-3′,5′), 154.0 (CO-2); LC-MS m/z 394 [M + H]+.
3.2. Molecular Modeling
All modeling was performed on a DELL 8 core system. For visualization and building the
structures Maestro (version 9.3) from Schrödinger (Schrödinger, LLC, New York, NY, USA, 2012)
was used (VEGF-R2 pdb code 2p2h, [23]). The illustrations of modeling were generated by Maestro.
For compound docking and screening the Schrödinger “Glide SP” workflow was used [28]. The goal
of the Glide methodology is to semiquantitatively rank the ability of candidate ligands to bind to a
specified conformation of the protein receptor. Prior to determining binding poses of ligands energetically
minimized compound conformations were generated, docked into the active site and subsequently
ranked based on their calculated binding affinity.
3.3. Biological Evaluation
All inhibitor solutions were prepared freshly in DMSO prior to each experiment and used immediately.
3.3.1. Selectivity Profiling of Compounds by IC50 Values Using 24 Protein Kinases
Recombinant protein kinases. The inhibitory profile of compounds was determined using the following
24 protein kinases (GenBankAcc.No. available on http://www.proqinase.com/pages/science [29]):
AKT1, ARK5, Aurora-A, Aurora-B, B-Raf-VE, CDK2/CycA, CDK4/CycD1, CK2-A1, EGF-R,
EPHB4, ERBB2, FAK, IGF1-R, SRC, VEGF-R2, VEGF-R3, FLT3, INS-R, MET, PDGFRβ, PLK1,
SAK, TIE2 and COT. All protein kinases were expressed using human cDNAs in Sf9 insect cells as
recombinat GST-fusion proteins or His-tagged proteins by means of the baculovirus expression
system. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or
Ni-NTA-agarose (Qiagen). The purity and identity of each kinase was determined by SDS-PAGE/silver
staining and western blot analysis using specific antibodies.
Protein kinase Assay. A proprietary protein kinase assay (33PanQinase® Activity Assay) was used
for measuring the kinase activity of the 24 protein kinases. All protein kinase assays were performed in
96-well FlashPlates™ (Perkin Elmer/NEN, Boston, MA, USA) in a 50 µL reaction volumes. Assays
for all enzymes were performed in a solution containing 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2,

Mar. Drugs 2013, 11
3220
3 mM MnCl2, 3 µM Na-orthovanadate, 1.2 mM DTT, 50 µg/mL PEG20000, 1 µM [γ-33P]-ATP
(approx. 5 × 105 cpm per well), recombinant protein kinase (50–400 ng). Depending upon the kinase
being assayed, appropriate substrates were used and were as follows (substrates shown in parentheses):
AKT1 (GSK3/14-27), ARK5 (autophosphorylation), Aurora-A, Aurora-B (Tetra(LRRWSLG)),
B-Raf-VE (MEK1 KM), CDK2/CycA (histone H1), CDK4/CycD1 (Rb-CTF), CK2-A1 (Casein),
EGF-R, EPHB4, ERBB2, FAK, IGF1-R, SRC, VEGF-R2, VEGF-R3 (poly(Glu,Tyr) 4:1), FLT3,
INS-R, MET, PDGFRβ (poly(Ala,Glu,Lys,Tyr) 6:2:5:1), PLK1 (Casein), SAK (autophosphorylation),
TIE2 (poly(Glu,Tyr) 4:1), COT (autophosphorylation). The IC50 values were measured by testing
10 concentrations of compounds by single sampling. The final DMSO concentration in the assay was
1% (v/v). The data were fitted using the 4-parameter logistic fit option of GraphPad Prism 5.
3.3.2. Cell Culture and Proliferative Assays using HL-60, TK 10, 786-0, M 14, and MCF-7 Cells
The cells were grown in RPMI 1640 Glutamax with 10% FCS, 100 µg/mL streptomycin and
100 U/mL Penicillin G and incubated in a 5% CO2 humidified atmosphere at 37 °C. For proliferation
experiments, cells were seeded in 20 µL pro well into 384-well Greiner 384 CellStar® plates (Greiner
Bio-One I. AG, Kremsmünster, AT). In addition to the test plates, one plate was prepared for the
reference measurement at day zero. All plates were incubated for 24 h at 37 °C in a humidified
atmosphere with 5% CO2. Compounds 5 and 8 that were dissolved in 100% DMSO (v/v) were added
to test plates using the Echo 550® Liquid Handler (Labcyte Inc., Sunnyvale, UK). The final DMSO
concentration in the assay was 0.5% v/v. The viability of the cells in the day zero control plates were
determined on the same day without adding any compounds. The CellTiter-Glo® Viability Assay was
used to determine the viability of cells using the standard protocol for this assay (Promega Corp.,
Madison, WI, USA). The luminescence signal was measured at the EnSpire® Multimode Plate Reader
(PerkinElmer, Waltham, MA, USA). Test plates were incubated for further 48 h and the cell viability
was defined as just described. Measured raw data were converted into percent of cell growth by using
the high control (0.5% DMSO v/v without compound) and the day zero control. For dose-response
studies, 11 different concentrations of compounds were tested in quadruplicates. The IC50 values were
calculated using the 4-parameter logistic fit option of GraphPad Prism 5.
4. Conclusions
In this study, we developed pyrazin-2(1H)-ones as potent and PDGFRβ inhibitors based on marine
derived hamacanthins. Modeling studies showed the core moiety of hamacanthins to bind in the ATP
binding pocket of RTK and suggested a straightforward strategy towards potent PDGFRβ binders. For
subsequent optimization of hamacanthin derivatives as PDGFRβ inhibitors, a flexible synthetic route
via microwave-mediated ring closure to asymmetric 3,5-substituted pyrazin-2(1H)-ones was
established and a set of novel compounds was produced. Herein, we identified highly potent PDGFRβ
binders with IC50 values in an enzymatic assay below µM range with compound 5 possessing
significant activity against PDGFR dependent cancer cells. Thus, marine hamacanthin-derived
pyrazin-2(1H)-ones showed interesting properties as lead for the further development of highly potent
and selective PDGFRβ-inhibitors.

Mar. Drugs 2013, 11
3221
Acknowledgments
We thank Martin Schütt for excellent technical assistance during synthesis at the Institute of
Pharmacy, Kiel and Janina Rahlff for excellent cell culture assistance at the European ScreeningPort
GmbH, Hamburg.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Haefner, B. Drugs from the deep: Marine natural products as drug candidates. Drug Discov.
Today 2003, 8, 536–544.
2. Gupta, L.; Talwar, A.; Chauhan, P.M. Bis and tris indole alkaloids from marine organisms: New
leads for drug discovery. Curr. Med. Chem. 2007, 14, 1789–1803.
3. Skropeta, D.; Pastro, N.; Zivanovic, A. Kinase inhibitors from marine sponges. Mar. Drugs 2011,
9, 2131–2154.
4. Kouko, T.; Matsumura, K.; Kawasaki, T. Total synthesis of marine bisindole alkaloids,
(+)-hamacanthins A, B and (−)-antipode of cis-dihydrohamacanthin B. Tetrahedron 2005, 61,
2309–2318.
5. Bao, B.; Sun, Q.; Yao, X.; Hong, J.; Lee, C.-O.; Cho, H.Y.; Jung, J.H. Bisindole alkaloids of the
topsentin and hamacanthin classes from a marine sponge Spongosorites sp. J. Nat. Prod. 2007,
70, 2–8.
6. Casapullo, A.; Bifulco, G.; Bruno, I.; Riccio, R. New bisindole alkaloids of the topsentin and
hamacanthin classes from the Mediterranean marine sponge Rhaphisia lacazei. J. Nat. Prod.
2000, 63, 447–451.
7. Peifer, C.; Bühler, S.; Hauser, D.; Kinkel, K.; Totzke, F.; Schaechtele, C.; Laufer, S. Design,
synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R
inhibitors. Eur. J. Med. Chem. 2009, 44, 1788–1793.
8. Peifer, C.; Kinkel, K.; Abadleh, M.; Schollmeyer, D.; Laufer, S. From five- to six-membered
rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors. J. Med. Chem. 2007, 50,
1213–1221.
9. Peifer, C.; Krasowski, A.; Hämmerle, N.; Kohlbacher, O.; Dannhardt, G.; Totzke, F.; Schaechtele,
C.; Laufer, S. Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-
pyrrole-2,5-dione(1) as a highly selective VEGF-R2/3 inhibitor. J. Med. Chem. 2006, 49,
7549–7553.
10. Peifer, C.; Selig, R.; Kinkel, K.; Ott, D.; Totzke, F.; Schaechtele, C.; Heidenreich, R.;
Röcken, M.; Schollmeyer, D.; Laufer, S. Design, synthesis, and biological evaluation of novel
3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor
receptor (VEGF-R) inhibitors. J. Med. Chem. 2008, 51, 3814–3824.
11. Jiang, B.; Yang, C.G.; Wang, J. Enantioselective synthesis for the (−)-antipode of the pyrazinone
marine alkaloid, hamacanthin A. J. Org. Chem. 2001, 66, 4865–4869.

Mar. Drugs 2013, 11
3222
12. Miyake, F.Y.; Yakushijin, K.; Horne, D.A. Synthesis of marine sponge bisindole alkaloids
dihydrohamacanthins. Org. Lett. 2002, 4, 941–943.
13. Zoraghi, R.; Worrall, L.; See, R.H.; Strangman, W.; Popplewell, W.L.; Gong, H.; Samaai, T.;
Swayze, R.D.; Kaur, S.; Vuckovic, M.; et al. Methicillin-resistant Staphylococcus aureus
(MRSA) pyruvate kinase as a target for bis-indole alkaloids with antibacterial activities. J. Biol.
Chem. 2011, 286, 44716–44725.
14. Caldwell, J.J.; Veillard, N.; Collins, I. Design and synthesis of 2(1H)-pyrazinones as inhibitors of
protein kinases. Tetrahedron 2012, 68, 9713–9728.
15. Dar, A.C.; Shokat, K.M. The evolution of protein kinase inhibitors from antagonists to agonists of
cellular signaling. Ann. Rev. Biochem. 2011, 80, 769–795.
16. Appelmann, I.; Liersch, R.; Kessler, T.; Mesters, R.; Berdel, W. Angiogenesis inhibition in cancer
therapy: Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF)
and their receptors: Biological functions and role in malignancy. Recent Results Cancer Res.
2010, 180, 51–81.
17. Koch, S.; Tugues, S.; Li, X.; Gualandi, L.; Claesson-Welsh, L. Signal transduction by vascular
endothelial growth factor receptors. Biochem. J. 2011, 437, 169–183.
18. Zhou, Y.; Chen, Y.; Tong, L.; Xie, H.; Wen, W.; Zhang, J.; Xi, Y.; Shen, Y.; Geng, M.; Wang, Y.;
et al. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour
activity via targeting VEGFR, FGFR and PDGFR. J. Cell. Mol. Med. 2012, 16, 2321–2330.
19. Noble, M.E.M.; Endicott, J.A.; Johnson, L.N. Protein kinase inhibitors: Insights into drug design
from structure. Science 2004, 303, 1800–1805.
20. Norman, R.A.; Toader, D.; Ferguson, A.D. Structural approaches to obtain kinase selectivity.
Trends Pharmacol. Sci. 2012, 33, 273–278.
21. Sachsenmaier, C.; Schachtele, C. Integrated technology platform protein kinases for drug
development in oncology. Biotechniques 2002, 33, S101–S106.
22. Heldin, C.H.; Westermark, B. Mechanism of action and in vivo role of platelet-derived growth
factor. Physiol. Rev. 1999, 79, 1283–1316.
23. Hodous, B.L.; Geuns-Meyer, S.; Hughes, P.; Albrecht, B.; Bellon, S.; Bready, J.; Caenepeel, S.;
Cee, V.; Chaffee, S.; Coxon, A.; et al. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,
3,5-triazine tie-2 kinase inhibitor. J. Med. Chem. 2007, 50, 611–626.
24. Garuti, L.; Roberti, M.; Bottegoni, G. Non-ATP competitive protein kinase inhibitors. Curr. Med.
Chem. 2010, 17, 2804–2821.
25. Peifer, C.; Stoiber, T.; Unger, E.; Totzke, F.; Schaechtele, C.; Marmé, D.; Brenk, R.; Klebe, G.;
Schollmeyer, D.; Dannhardt, G. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides
as angiogenesis inhibitors. J. Med. Chem. 2006, 49, 1271–1281.
26. Reiterer, G.; Yen, A. Platelet-derived growth factor receptor regulates myeloid and monocytic
differentiation of HL-60 cells. Cancer Res. 2007, 67, 7765–7772.
27. Johannes, E.; Horbert, R.; Schlosser, J.; Schmidt, D.; Peifer, C. Effective synthesis of
3,5-diaryl-(1H)-pyrazin-2-ones via microwave mediated ring closure. Tetrahedron Lett. 2013, 54,
4067–4072.

Mar. Drugs 2013, 11
3223
28. Halgren, T.A.; Murphy, R.B.; Friesner, R.A.; Beard, H.S.; Frye, L.L.; Pollard, W.T.; Banks, J.L.
Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database
screening. J. Med. Chem. 2004, 47, 1750–1759.
29. ProQinase Targeting Cancer. Available online: http://www.proqinase.com (accessed on
19 August 2013).
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).